医学
乳腺癌
芳香化酶
兴奋剂
内科学
促性腺激素释放激素激动剂
肿瘤科
雌激素
激素
内分泌系统
卵巢癌
芳香化酶抑制剂
内分泌学
促性腺激素释放激素
癌症
妇科
受体
促黄体激素
作者
M. de Ciantis,Christelle Fauré,Isabelle Ray‐Coquard,Olivier Trédan,Christine Rousset‐Jablonski
标识
DOI:10.1016/j.jogoh.2018.03.002
摘要
In premenopausal women treated for breast cancer, endocrine therapy combining an aromatase inhibitor (AI) and a gonadotropin-releasing hormone (GnRH) agonist (GA) for ovarian suppression may be indicated in high-risk or in metastatic cancer. AIs are effective in premenopausal women only when ovarian estrogen production is suppressed, a state achievable through the use of GAs. However, a complete suppression sometimes proves elusive. We report here three cases of ovarian suppression failure in premenopausal breast cancer patients who received adjuvant AI+GA. Frequency of GA administration, BMI, and young age could affect gonadotropin suppression and may be implied in these failures. Clinical monitoring of these patients is advisable, and hormone assays and pelvic ultrasound should be performed in case of symptoms of estrogen activity.
科研通智能强力驱动
Strongly Powered by AbleSci AI